Nandrolone

Quick links to important sections

Nandrolone

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nandrolone

Property Description
Active Ingredient Nandrolone (as Decanoate or Phenylpropionate ester)
Form Injectable Solution
Pharmacological Class Anabolic-Androgenic Steroid (AAS), Steroid Hormone
General Purpose Promote Anabolism, Counteract Catabolism
Origin Synthetic (derived from Testosterone)

What Type of Medicine is Nandrolone?

Nandrolone is a synthetic steroid hormone classified as an anabolic-androgenic steroid (AAS), a recognized pharmacological class. It is chemically known as 19-nortestosterone because it is structurally derived from the natural hormone testosterone but lacks a carbon atom at the 19th position. The core molecule, Nandrolone (C18H26O2), functions as an androgen receptor agonist, mediating its biological effects by binding to specific cellular receptors. This structural modification grants it a significantly higher ratio of anabolic (tissue-building) activity relative to its androgenic (masculinizing) effects compared to testosterone, a property central to its clinical use.


Composition and Available Pharmaceutical Form

Nandrolone is supplied as a single-ingredient injectable solution intended for parenteral administration via injection. The active ingredient is typically manufactured with a long-acting ester chain, such as Nandrolone Decanoate or Nandrolone Phenylpropionate, which influences the compound's release rate. To facilitate the sustained absorption profile required for these esters, the active agent is dissolved within an oleaginous vehicle (an oil base), creating the final medicinal solution. Nandrolone is exclusively a prescription-only substance (Rx) worldwide due to its hormonal classification.


General Purpose and Principal Biological Effect

The primary general purpose of Nandrolone is to actively promote anabolism and counteract the loss of tissues caused by systemic catabolism. Its mechanism enhances the body's capacity for tissue repair by stimulating protein synthesis and improving overall nitrogen balance—a process fundamental for constructing and maintaining cellular structures. Furthermore, the substance is known to stimulate erythropoiesis, or the production of red blood cells; this effect supports enhanced oxygen-carrying capacity, contributing to systemic vitality and recovery. Clinical recognition exists for its role in supporting tissue accrual in appropriate patient populations.

What side effects are possible with Nandrolone?

Possible Side Effects and Safety Information

The safety profile of Nandrolone is structurally defined by its hormonal nature, leading to two main categories of risk: androgenic effects and hepatobiliary complications. Adverse reactions are officially classified across several System-Organ Classes as documented in regulatory texts.


Official Adverse Reactions and Risk Categories

Commonly documented effects include those related to hormonal and metabolic function. These include fluid retention (oedema), acne, changes in blood lipid profiles (decreased mathrmHDL, increased mathrmLDL), and increased red blood cell count (polycythaemia).

Androgenic effects are a primary concern, particularly in females and prepubertal males. In females, virilisation (e.g., voice deepening, hirsutism, clitoral enlargement) is a risk that is explicitly noted in official labeling as being often irreversible even after treatment discontinuation. In children, there is a risk of premature epiphyseal closure, which can impair final adult stature.


Serious Adverse Reactions and Safety Constraints

Official prescribing information highlights rare but serious risks associated with anabolic steroid therapy, typically linked to long-term exposure. These include hepatic peliosis (formation of blood-filled cysts in the liver or spleen) and the potential development of liver tumors (adenomas or carcinomas).

Safety Constraints: Nandrolone is officially contraindicated in patients with known or suspected prostate cancer or male breast cancer. It is also contraindicated in patients with severe hepatic impairment or nephrotic syndrome. Patients with pre-existing cardiac or renal conditions require observation due to the risk of severe fluid retention and cardiac decompensation. These documented classifications establish the necessity for specific safety observations for populations such as children and females, and they define the conditions under which the medication must not be used (contraindications).

Overdose and Emergency Response

The official regulatory profile for Nandrolone states that no reports of acute overdosage in humans have been documented in prescribing information. The known clinical profile for overexposure is instead defined by the severe consequences resulting from the exaggeration of the drug’s hormonal and toxic effects.

Manifestations of overexposure requiring attention often relate to signs of excessive androgenic activity. In women, this may include the development of virilization, such as deepening of the voice, hirsutism, and clitorimegaly. In men, manifestations include inhibition of testicular function and gynecomastia.

Urgent Medical Attention is Required when specific, severe manifestations appear, as mandated by official prescribing information. The drug must be immediately discontinued and medical assistance sought upon the detection of signs of hypercalcemia or the first evidence of mild virilism in female patients, as some changes may become irreversible.

Overexposure is also associated with potentially severe outcomes, including peliosis hepatis (blood-filled cysts in the liver), hepatocellular neoplasms, and edema that may lead to congestive heart failure. Management for overexposure is symptomatic and supportive, as no specific antidote is known. For prepubertal children, regulatory labels note the risk of premature closure of the epiphyses, a critical, population-specific consideration. This structure reflects the guidance of authorities like the FDA and EMA.

Therapeutic Uses of Nandrolone

What Nandrolone Treats: Main Uses and Benefits

Nandrolone is an anabolic androgenic steroid whose primary therapeutic role is relevant in contexts involving heightened systemic burden. It may be part of symptomatic management for several conditions presenting with systemic or localized discomfort.

Nandrolone decanoate is commonly used across conditions presenting with acute episodes and may assist with managing symptoms that interfere with daily comfort. The medication is applied in addressing temporary physiological imbalance, and may assist with general well-being during symptomatic phases. Its primary indications include certain types of anaemia, particularly anaemia associated with chronic kidney failure, and is useful in scenarios where symptoms escalate temporarily. Other uses include osteoporosis (loss of bone tissue), and as palliative treatment for advanced inoperable mammary carcinoma.

The medication is commonly used in clinical settings that involve acute or unstable symptom patterns, and is applied in addressing symptoms related to systemic imbalance. It supports patients during difficult episodes by easing distress and is considered relevant in clinical scenarios where increased physiological stress, such as that related to long-term corticosteroid use, affects functional stability. One key benefit is that it supports the rebuilding of weakened tissues and can contribute to the maintenance of lean body mass.

“The medicine helps to maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Is commonly used to help with symptoms related to systemic imbalance

Regulatory References

  1. NPS MedicineWise overview of Deca-Durabolin

Eligibility and Restrictions for Use

The eligibility for Nandrolone use is strictly defined by government regulatory documents, establishing absolute prohibitions and requiring stringent monitoring for specific populations.

Populations for Whom Use is Contraindicated

The medicine must not be used in patients with:

  • Carcinoma of the Prostate or Carcinoma of the Breast (in males).
  • Nephrosis or the nephrotic phase of nephritis.
  • Pregnancy (categorized as Pregnancy Category X) due to the risk of masculinization of the female fetus.
  • Breastfeeding/Lactation (Contraindicated/Not recommended).

Conditional Eligibility and Restrictions

Use is allowed only under special caution and monitoring in the following groups:

  • Major Organ Impairment: Patients with pre-existing cardiac, renal, or hepatic disease require caution due to the risk of fluid retention and edema.
  • Anticoagulant Users: Patients taking oral anticoagulants require close monitoring and possible dosage adjustment as Nandrolone may increase the anticoagulant effect.
  • Pediatric Patients: Use is limited to specific conditions in children ages 2 to 13. Periodic X-ray examinations of bone age are mandatory to monitor for premature closure of the growth plates.
  • Geriatric Patients: Older adult males may face an increased risk for prostatic hypertrophy and prostatic carcinoma.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Nandrolone

Interaction Scope

Property Details (Strictly from Regulatory Documents)
Medicinal product categories with documented interactions: Oral Anticoagulants, Insulin and Oral Antidiabetic Agents, Adrenal Steroids (Corticosteroids), and Adrenocorticotropic Hormone (ACTH).
Specific interacting medicines (if explicitly listed): Warfarin (noted for increased serum concentration/effect).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic: Suppression of clotting factors; Additive effects on blood glucose and fluid/electrolyte balance.
Timing-based interaction rules (if applicable): None specified.
Population-specific interaction notes (if applicable): The additive edema risk with corticosteroids/ACTH is specifically cautioned in patients with pre-existing cardiac, renal, or hepatic disease.
Interaction-related restrictions: None officially documented as a formal drug-drug contraindication; interactions require procedural constraints.

Interaction Classifications (High-Level)

Property Details (Strictly from Regulatory Documents)
Interaction severity classification (as defined in official documents): Clinically Significant Interactions (requiring close patient monitoring).
Regulatory basis (EMA / FDA / etc.): Official government prescribing information.
Interaction-context constraints (as defined in official documents): The increased edema risk with corticosteroids is constrained by the presence of underlying cardiac, renal, or hepatic disease.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Oral Anticoagulants may increase the serum concentration and anticoagulant effect of the anticoagulant.
  • Interaction with anticoagulants is officially associated with the suppression of clotting factors (II, V, VII, and X) and an increase in prothrombin time.
  • The blood glucose-lowering effects of Insulin and Oral Antidiabetic Agents are enhanced.
  • Concomitant use with Adrenal Steroids or ACTH may lead to increased fluid retention and add to the risk or severity of edema.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents define the Nandrolone interaction structure primarily through pharmacodynamic reinforcement across three major classes of co-administered medicines. This structure identifies potential outcomes such as altered blood coagulation, enhanced blood sugar reduction, and additive fluid retention. Official information specifies that these interactions necessitate close monitoring of the co-administered medicine and a possible dosage adjustment, reflecting a clinically significant classification.

Mechanism of Action

Nandrolone functions as an androgen receptor (AR) agonist. Following systemic distribution, nandrolone, or its 5alpha-reduced metabolite dihydronandrolone, passively diffuses across the cell membrane into target cells, including those in skeletal muscle and bone. Intracellularly, the molecule binds with high affinity to the cytoplasmic AR. This binding event induces a conformational change in the AR, resulting in the dissociation of chaperone proteins and the translocation of the activated steroid-receptor complex into the nucleus. Within the nucleus, the complex binds to specific Androgen Response Elements (AREs) located in the promoter regions of target genes. This DNA-binding modulates the rate of gene transcription, specifically enhancing the transcription of genes involved in protein synthesis and nitrogen retention. The resulting increase in mRNA for these target genes leads to an augmented ribosomal translation and subsequent protein accretion. Furthermore, nandrolone exhibits a lower relative binding affinity for the 5alpha-reductase enzyme compared to testosterone, resulting in a reduced conversion to its 5alpha-reduced metabolite in certain tissues. System-level consequences include modulation of muscle tissue anabolism and bone matrix density.

Dosage and Administration Information

How to Use Nandrolone Decanoate

The following instructions summarize the administration guidelines for Nandrolone Decanoate, based on standardized prescribing information.


Administration Details

Administration Scope Official Guideline
Route of Administration Must be given by deep intramuscular injection only, preferably into the gluteal muscle.
Dosing Schedule Male: 100 to 200 mg per week. Female: 50 to 100 mg per week. Dosage is determined and adjusted based on the patient's therapeutic response.
Frequency Pattern Typically administered weekly, though adjusted by the prescribing physician.
Age-Group Rules Dosing is specified for adults (male/female). Dosage for children is not established in summary instructions.
Special Conditions Treatment should be intermittent when possible. The drug is considered adjunctive therapy, requiring patients to receive adequate nutritional support (e.g., iron for refractory anemia).

Procedural Structure

The correct use of Nandrolone Decanoate follows a protocol overseen by a healthcare professional:

  1. Establish Dosage: A physician assesses the patient's condition to determine the appropriate starting dose, which falls within the official ranges (e.g., 100–200 mg per week for men).
  2. Injection Procedure: The medication is administered via deep intramuscular injection into the selected site, most commonly the gluteal muscle.
  3. Nutritional Support: The patient must ensure consumption of adequate nutrients (like iron) to maximize the therapeutic effect, as the medicine is an adjunct.
  4. Monitoring and Duration: The patient's response is continually monitored to assess effectiveness, with the goal of keeping the duration of therapy intermittent when clinically appropriate.

Note: These guidelines define the standardized method for using the medication, focusing solely on the procedural steps for administration.

Recent Clinical Evidence

Nandrolone: Recent Clinical Evidence


Evidence for Use in HIV-Associated Wasting Syndrome

Research into Nandrolone has primarily centered on studies examining outcomes in adults experiencing body weight loss related to HIV infection. The main evidence comes from short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews of those studies. Researchers designed these trials to explore how Nandrolone affected body composition, particularly the non-fat tissues known as Lean Body Mass (LBM). The findings from these studies consistently describe measured changes in Lean Body Mass and total body weight over the short study periods when compared to control groups receiving a placebo. What is known from this research applies only to the specific populations studied, and the follow-up durations were limited, often lasting only three to six months.


Evidence for Use in Osteoporosis

The evidence for Nandrolone's use in bone health primarily involves studies in postmenopausal women and older women diagnosed with osteoporosis. This research base includes a combination of older clinical trials and systematic reviews. Researchers aimed to evaluate outcomes related to bone tissue, specifically measuring changes in Bone Mineral Density (BMD) and monitoring the incidence of new bone fractures. Systematic reviews reported patterns where measurements related to vertebral fractures were recorded in the study groups. A key limitation is that many of the original clinical trials have modest sample sizes, and comparative evidence is lacking in relation to other available therapeutic options for osteoporosis.


Synthesis of Evidence Gaps and Uncertainty

Across all indications, the major gap is that long-term effects are not fully established. The limited information for long-term outcomes makes it difficult to draw conclusions about the sustained effects or durability of the observed short-term changes. Furthermore, the sample sizes were modest in the foundational trials, and evidence quality varies across studies. Research provides context but not individual predictions, and the evidence highlights what is known and what is still uncertain.

Key Studies & References

  1. Nandrolone Decanoate Injection USP Drug Label: Indications and Usage, Contraindications
  2. Anabolic Steroids (Nandrolone): Mechanisms and Use in Wasting and Anemia

Frequently Asked Questions (FAQ)

Common questions about Nandrolone (FAQ)

Q: Is Nandrolone the same as testosterone?

Nandrolone is a synthetic steroid that is chemically derived from the natural hormone testosterone. This chemical modification is associated with Nandrolone having a significantly higher ratio of anabolic (tissue-building) activity compared to its androgenic (masculinizing) activity.

Q: Why do official medical sources sometimes list it as Nandrolone decanoate?

Official sources list the medicine as 'Nandrolone Decanoate' because the active ingredient is chemically attached to a decanoate ester chain. This chain controls the rate at which the active drug is released into the body following an injection, providing a prolonged duration of action.

Q: What kind of conditions is Nandrolone typically prescribed for?

Nandrolone is indicated for the management of the anemia of renal insufficiency and is used as an adjunct to help manage catabolic processes, which involve tissue loss, in certain conditions such as chronic infections or severe trauma. It is also indicated for the palliative treatment of certain types of breast cancer in postmenopausal women.

Q: How quickly does Nandrolone begin to have an effect after starting treatment?

Following a deep intramuscular injection of Nandrolone Decanoate, the active substance typically reaches its peak concentration, or highest level, in the body over a period of about three to six days.

Q: How long does the effect of Nandrolone last in the body?

Regulatory data on Nandrolone Decanoate, a long-acting form, indicates that the active substance has an elimination half-life between 6 and 12 days. This prolonged release profile results in a duration of biological effect lasting approximately two to three weeks after a deep intramuscular injection.

Q: What happens if a dose of Nandrolone is missed?

Since this medicine is administered via injection by a healthcare professional, the official process upon missing an appointment for a scheduled dose is to contact the prescribing physician or clinic as soon as possible to arrange the next injection.

Q: Are there common signs that the Nandrolone treatment is working?

Signs that the treatment is working are related to the specific medical condition being addressed. For example, official labeling indicates that improvement in anemia may include observed increases in hemoglobin and red cell mass. In catabolic states, improvement is associated with enhanced protein synthesis and nitrogen retention.

Q: Can Nandrolone affect mood or mental state?

Official safety information for the class of anabolic steroids indicates that high doses may be associated with changes in mood and behavior. These effects can include experiencing mood swings and increased feelings of hostility or aggression.

Q: Is hair loss listed as a potential side effect?

Although Nandrolone has weak androgenic effects, the stimulation of hair follicles is listed as potentially leading to hair loss (alopecia). This effect is listed alongside other androgenic changes like hirsutism (excess hair growth) and acne.

Q: Does Nandrolone cause weight gain?

The medicine is designed to promote tissue building, known as anabolism, by increasing protein synthesis and improving nitrogen balance. Because of this mechanism, clinical studies have reported measured increases in a patient's lean body mass and total body weight during treatment.

Q: What is meant by the term 'virilization' in relation to Nandrolone use?

Virilization refers to the development of male characteristics, which is a potential risk for female patients. Official product information lists signs such as deepening of the voice, unusual hair growth (hirsutism), acne, and changes to the menstrual cycle. Regulatory documents note that these androgenic effects are often irreversible, even after the medicine is discontinued.

Q: Is Nandrolone safe for use in children or adolescents?

Use in children is restricted to specific medical conditions and requires careful monitoring due to the risk of accelerating bone maturation. This may compromise a child's final adult stature. Monitoring includes periodic X-ray examinations of the wrist and hand to assess bone age throughout the treatment period.

Q: Are there any common foods or supplements that interact with Nandrolone?

Regulatory guidelines state that the medicine is considered adjunctive therapy, meaning it is used in addition to other measures. Official guidelines emphasize the importance of receiving adequate nutritional support, such as sufficient iron intake when treating anemia, to ensure the maximum therapeutic benefit.

Q: Can Nandrolone be used with pain medications?

Regulatory documents specifically cite an interaction with a class of drugs known as Adrenal Steroids (Corticosteroids), noting that taking them together may increase the risk of fluid retention (edema). Interactions with other classes of pain medications are not explicitly cited in core regulatory documents.

Q: What is the risk of an allergic reaction to Nandrolone?

The official safety data focuses primarily on hormonal and hepatobiliary risks. While no specific text on common allergic reactions is present in the core summaries, as with all injectable medicines, there is a general potential for hypersensitivity reactions.

Q: Is there a maximum length of time Nandrolone is typically used for?

The duration of treatment is guided by the patient's specific condition and their therapeutic response to the medicine. For some indications, such as anemia, official labels suggest discontinuation if no improvement is seen within the first six months. Overall, official documents recommend that the duration of therapy be kept intermittent whenever clinically appropriate.

Q: How is Nandrolone classified in terms of controlled substances?

In the United States, Nandrolone is classified as a Schedule III controlled substance under the Controlled Substances Act. This classification reflects a recognized potential for abuse, which means specific regulations govern how it is prescribed and dispensed.

Q: What does the latest research say about Nandrolone's use in anemia?

Nandrolone Decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass in these clinical settings. To ensure the best response, regulatory labeling notes that adequate iron intake is required as an adjunct to the treatment.

Q: Does Nandrolone treatment require regular blood tests?

Yes, regulatory documents indicate that monitoring includes regular laboratory testing. This includes periodic blood checks of hemoglobin and hematocrit to monitor for a condition called polycythemia (excess red blood cells). Blood tests for the serum lipid profile, which includes cholesterol, are also required.

Q: Is Nandrolone approved for use in all countries?

While Nandrolone maintains regulatory approval in many major jurisdictions, its clinical use is declining globally. According to regulatory monographs, its sale and availability have been discontinued in several countries worldwide.

Q: Does Nandrolone have a risk of dependence or misuse?

Yes, Nandrolone is classified as a Schedule III controlled substance in the US. This classification reflects a recognized potential for abuse and physical or psychological dependence, which is the basis for its strict prescription-only status.

Q: Why is Nandrolone sometimes discussed in sports or athletic contexts?

Regulatory documents state that the drug has not been proven safe or effective for enhancing athletic performance. Nandrolone is also listed by organizations like the World Anti-Doping Agency (WADA) as a prohibited substance in competitive sports.

Q: Are there specific symptoms that require immediate medical attention while using Nandrolone?

Official labeling advises that specific signs should be reported immediately if they occur. These may include voice changes (hoarseness), severe nausea or vomiting, changes in skin color such as jaundice, or sudden and excessive swelling (edema) in the ankles.

Q: Can Nandrolone be detected in drug screening tests?

Since the drug is a controlled substance and is on the prohibited list of major anti-doping organizations, it is detectable in drug screening tests designed to identify the presence of anabolic-androgenic steroids.

Q: Does Nandrolone affect blood pressure?

Yes, regulatory documents note that the medicine may increase the risk of fluid retention and edema, especially when used with corticosteroids. This increase in fluid retention is cited as a safety concern for patients with pre-existing cardiac or renal conditions.

Q: Is it necessary to stop taking other medications before starting Nandrolone?

Regulatory guidance focuses on careful management of existing medicines. It generally requires close monitoring and possible dosage adjustment for interacting medications, such as oral anticoagulants and diabetes medicines, but official guidance does not explicitly state that other medications must be stopped.

Q: What happens when treatment with Nandrolone is stopped?

Upon discontinuation, many adverse reactions may subside. However, official safety warnings note that some androgenic effects, such as virilization (e.g., voice deepening) in women, are often irreversible even after the medicine is stopped.

Q: What is the difference between Nandrolone decanoate and Nandrolone phenylpropionate?

Both Nandrolone Decanoate and Nandrolone Phenylpropionate are forms of the drug with an ester chain attached to control the release rate. Official literature notes that the Decanoate form provides a significantly longer duration of action in the body compared to the Phenylpropionate form.

Q: Is Nandrolone listed as a doping agent?

Yes, Nandrolone is classified as an anabolic-androgenic steroid and is explicitly listed as a prohibited substance by the World Anti-Doping Agency (WADA) and other sports regulatory bodies.

Q: What does 'Androgenic' mean in the context of Nandrolone?

Androgenic effects relate to the development and maintenance of masculine characteristics in the body. Official regulatory documents describe Nandrolone as having a structure that gives it relatively weak androgenic effects compared to its strong anabolic (tissue-building) effects.

Q: What is the official definition of 'anabolic' effect?

The anabolic effect is the medicine's primary action, which is described in official documents as enhancing the body’s ability to build and maintain tissue. This is achieved by stimulating protein synthesis and improving the overall nitrogen balance within the body.

Q: What patient monitoring is generally required during Nandrolone therapy?

Monitoring during Nandrolone therapy includes periodic checks of hemoglobin and hematocrit to watch for polycythemia (an increased red blood cell count) and serum lipid profiles for changes in cholesterol. For children, bone age X-rays are also a required part of the monitoring protocol.

Q: Is it normal if the Nandrolone injection site is sore?

Administration guidelines recommend monitoring the deep intramuscular injection site for pain, swelling, and irritation. While some minor soreness may occur, if prolonged or excessive site reactions occur, they should be brought to the attention of the prescribing professional.

How should Nandrolone be stored and disposed of?

Storage and Disposal of Nandrolone Injection

Nandrolone injectable solution must be stored and handled according to the instructions on its official regulatory label to ensure stability and safety.


Mandatory Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C). Do not freeze.
Protection Keep in the original container and protect from light.
Child Safety Must be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Nandrolone, and any waste materials, must be handled in accordance with local regulations. Used needles and syringes must be placed immediately into a designated sharps disposal container. The medicine should not be disposed of in household waste or flushed down wastewater; a medicine take-back program is typically recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nandrolone found in:

A-Z Index: